BCYC - Bicycle Therapeutics gains on early-stage data for oncology asset in bladder cancer

Bicycle Therapeutics (NASDAQ:BCYC) is trading sharply higher on Friday after the clinical-stage biotech announced promising interim Phase I results for its cancer candidate BT8009 in a group of patients with solid tumors. The data were shared at the ongoing 2022 American Association for Cancer Research (AACR) Annual Meeting. The preliminary monotherapy dose-escalation results were generated from the Phase I/II trial, which involved patients with solid tumors linked to Nectin-4 expression, who had not received the antibody-drug conjugate, enfortumab vedotin. Out of 34 patients, there were preliminary confirmed responses among patients with urothelial carcinoma who received BT8009 at 5 mg/m2. Half of the patients indicated (4/8) a complete response (CR) or partial response (PR), including 1/8 patients with a CR and 3/8 patients with a PR. With two patients showing stable disease (SD), the overall response rate and disease control rate among UC patients for the cohort stood at 50% and

For further details see:

Bicycle Therapeutics gains on early-stage data for oncology asset in bladder cancer